^
Association details:
| Biomarker: | RAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type “window of opportunity”
Published date:
10/09/2018
Excerpt:
15 mCRC patients harboring any RAS mutation in tumor tissue....5 of them have received EGFR inhibitors as a second-line treatment, achieving a durable clinical benefit.
DOI:
10.1093/annonc/mdy281.095
